Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, Aclidinium Bromide suppressed the PI3K/AKT signaling pathway in lung cancer A549 cells.
|
31128006 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, cotreatment with sesamin and CAY10404 markedly reduced the levels of phosphorylated protein kinase B (pAkt) and phosoinositide 3 kinase (PI3K) in three lung cancer cell lines.
|
30365050 |
2019 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
|
31158500 |
2019 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Consistently, DOK7V1 overexpression in lung cancer cells suppressed the phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathways, but activated the focal adhesion kinase (FAK)/paxillin signaling pathway.
|
30431081 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long non-coding RNA OECC promotes cell proliferation and metastasis through the PI3K/Akt/mTOR signaling pathway in human lung cancer.
|
31452780 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Co-mutations in <i>TP53</i> and the <i>PI3K/AKT/mTOR</i> pathway confer additional resistance to anti-HER2 treatments in lung cancer.
|
31748336 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, targeting the PI3K pathway may be a potential therapeutic strategy that prevents the structural skeletal damage associated with bone metastasis of lung cancer.
|
30896825 |
2019 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MicroRNA-374b accelerates the development of lung cancer through downregulating PTEN expression via activating PI3K/Akt pathway.
|
30779080 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phosphoinositide 3-kinase (PI3K)/AKT/mechanistic target of rapamycin (mTOR) signaling has been shown to contribute to tumorigenesis, tumor progression, and resistance to therapy in most human cancer types, including lung cancer.
|
31262325 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual molecular targeted therapy for mTOR and PI3K may be a promising therapeutic strategy in the specific population of patients with lung cancer with LKB1 loss.
|
30825612 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inotilone from Inonotus linteus suppresses lung cancer metastasis in vitro and in vivo through ROS-mediated PI3K/AKT/MAPK signaling pathways.
|
30787353 |
2019 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we identified that the PI3K-AKT and epilthelial-mesenchymal transition (EMT) signaling pathways were inhibited by miR-3666 overexpression in lung cancer cells.
|
30481052 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
All of these results suggested that the lncRNA FER1L4 suppressed cell proliferation and metastasis by inhibiting the PI3K/Akt signaling pathway in lung cancer.
|
31115514 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
To date, PI3K inhibitors have not been approved for lung cancer.
|
31337981 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fibroblast activation protein-α promotes the growth and migration of lung cancer cells via the PI3K and sonic hedgehog pathways.
|
29115573 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Methyl nonanoate, (R)-citronellol, cis-carveol (L-carveol), 3-methyl-Cyclohexanone, 4-carene and thujopsene were finally screened for PI3K targeted anti-cancer therapies which may find direct application as inhalers or sprays against lung cancer as these compounds are highly volatile.
|
28356026 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mechanism may involve of PI3K/AKT signaling pathways in A549 cells, which may a potential therapeutic target for the treatment of lung cancer.
|
30344755 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results show that lutein inhibits the PI3K/AKT signaling pathway and induces apoptosis in A549, which may therefore be used as a potent natural anticancer drug with no side effects to treat lung cancer.
|
30806240 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effect of miR-21 on Apoptosis in Lung Cancer Cell Through Inhibiting the PI3K/ Akt/NF-κB Signaling Pathway in Vitro and in Vivo.
|
29669316 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
RAS signaling through PI3K is necessary for normal lymphatic vasculature development and for RAS-induced transformation in vitro and in vivo, especially in lung cancer, where it is essential for tumor initiation and necessary for tumor maintenance.
|
28847905 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings demonstrate that PI3K/AKT/YY1 is involved in the regulation of lung cancer cell behavior induced by IL‑13, and miR‑29a represents a promising therapeutic target.
|
29620222 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The RAS-PI3K interaction is thus an important signaling node and potential therapeutic target in EGFR-mutant lung cancer, even though RAS oncogenes are not themselves mutated in this setting, suggesting different strategies for tackling tyrosine kinase inhibitor resistance in lung cancer.
|
30590030 |
2018 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
|
29961813 |
2018 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compared with those in the control group, expression of PI3K and Akt in the lung cancer cells H1299 after EGCG treatment showed no significant differences (p>0.05), while expression levels of p-PI3K and p-Akt were significantly reduced (p<0.05).
|
30058690 |
2018 |
Malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
|
29516506 |
2018 |